TY - JOUR
T1 - Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study
AU - Nishimoto, Norihiro
AU - Amano, Koichi
AU - Hirabayashi, Yasuhiko
AU - Horiuchi, Takahiko
AU - Ishii, Tomonori
AU - Iwahashi, Mitsuhiro
AU - Iwamoto, Masahiro
AU - Kohsaka, Hitoshi
AU - Kondo, Masakazu
AU - Matsubara, Tsukasa
AU - Mimura, Toshihide
AU - Miyahara, Hisaaki
AU - Ohta, Shuji
AU - Saeki, Yukihiko
AU - Saito, Kazuyoshi
AU - Sano, Hajime
AU - Takasugi, Kiyoshi
AU - Takeuchi, Tsutomu
AU - Tohma, Shigeto
AU - Tsuru, Tomomi
AU - Ueki, Yukitaka
AU - Yamana, Jiro
AU - Hashimoto, Jun
AU - Matsutani, Takaji
AU - Murakami, Miho
AU - Takagi, Nobuhiro
PY - 2013
Y1 - 2013
N2 - Objectives: To evaluate the safety and efficacy of retreatment with tocilizumab (TCZ) in patients who had participated in the DREAM study (Drug free remission/low disease activity after cessation of tocilizumab [Actemar] monotherapy study) and had experienced loss of efficacy. Methods: Patients were retreated with TCZ or other disease modifying antirheumatic drugs (DMARDs). Disease activity was measured using the 28-joint disease activity score (DAS28) for 12 weeks. Results: A total of 164 eligible patients, including 161 who experienced loss of efficacy within 52 weeks of the DREAM study, resumed treatment: 157 with TCZ and 7 with DMARDs and/or infliximab. Of TCZ-treated patients, 88.5 % (139 patients) achieved DAS28 <2.6 within 12 weeks, whereas among patients treated with DMARDs and/or infliximab only 14.3 % (1 patient) achieved DAS28 <2.6. Adverse events were observed in 70 TCZ-treated patients (44.0 %), but no serious infusion reactions were observed. Conclusions: Retreatment with TCZ was well-tolerated and effective in patients who had responded to the preceding TCZ monotherapy but had experienced loss of efficacy after cessation of TCZ.
AB - Objectives: To evaluate the safety and efficacy of retreatment with tocilizumab (TCZ) in patients who had participated in the DREAM study (Drug free remission/low disease activity after cessation of tocilizumab [Actemar] monotherapy study) and had experienced loss of efficacy. Methods: Patients were retreated with TCZ or other disease modifying antirheumatic drugs (DMARDs). Disease activity was measured using the 28-joint disease activity score (DAS28) for 12 weeks. Results: A total of 164 eligible patients, including 161 who experienced loss of efficacy within 52 weeks of the DREAM study, resumed treatment: 157 with TCZ and 7 with DMARDs and/or infliximab. Of TCZ-treated patients, 88.5 % (139 patients) achieved DAS28 <2.6 within 12 weeks, whereas among patients treated with DMARDs and/or infliximab only 14.3 % (1 patient) achieved DAS28 <2.6. Adverse events were observed in 70 TCZ-treated patients (44.0 %), but no serious infusion reactions were observed. Conclusions: Retreatment with TCZ was well-tolerated and effective in patients who had responded to the preceding TCZ monotherapy but had experienced loss of efficacy after cessation of TCZ.
KW - Drug free
KW - Interleukin 6
KW - Retreatment
KW - Rheumatoid arthritis
KW - Tocilizumab
UR - http://www.scopus.com/inward/record.url?scp=84877665920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877665920&partnerID=8YFLogxK
U2 - 10.1007/s10165-013-0895-y
DO - 10.1007/s10165-013-0895-y
M3 - Article
SP - 1
EP - 7
JO - Japanese Journal of Rheumatology
JF - Japanese Journal of Rheumatology
SN - 1439-7595
ER -